We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 30, 2022

Overall Survival With First-Line Palbociclib Plus Letrozole vs Placebo Plus Letrozole in Women With ER+/HER2− Advanced Breast Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2
J. Clin. Oncol 2022 Jun 08;40(17_suppl)LBA1003, RS Finn, HS Rugo, VC Dieras, et al

Further Reading